Synergetics USA, Inc. (NASDAQ: SURG), a medical device company that designs, manufactures, and markets innovative microsurgical instruments for ophthalmic and neurosurgical applications, announced its results for the first quarter ended October 31, 2009. The Company reported first quarter 2010 sales of $12.1 million and net income of $542,000. Related posts China Pharmaceuticals, Inc. Announces Record [...]

Continue reading " Synergetics Announces First Quarter Results "

Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) reported results for the quarter ended October 31, 2009. For the three months ended October 31, 2009, the Company reported net sales of $40.9 million, an increase of 63% from $25.1 million for the same period last year. Related posts China Pharmaceuticals, Inc. Announces Record Sales for First Quarter [...]

Continue reading " Hi-Tech Pharmacal Reports Sales and Earnings for the Second Fiscal Quarter Ended October 31, 2009 "

Synergetics USA, Inc. (NASDAQ: SURG), a medical device company that designs, manufactures, and markets innovative microsurgical instruments for ophthalmic and neurosurgical applications, announced its results for the fourth quarter and fiscal year ended July 31, 2009. The Company reported fourth quarter 2009 sales of $13.9 million and net income of $87,000. Sales for fiscal year [...]

Continue reading " Synergetics Reports Fourth Quarter and Fiscal 2009 Results "

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA) (FF: PV3), a drug delivery company with two of the only three ophthalmic sustained release delivery products approved by the FDA for treatment of back of the eye diseases, announced financial results for its fourth quarter and fiscal year ended June 30, 2009. For the quarter ended June 30, [...]

Continue reading " pSivida Corp. Reports Results for the Fourth Quarter and Fiscal Year Ended June 30, 2009 "

Fera Pharmaceuticals has acquired all rights, title and interest to seven prescription sterile anti-infective ophthalmic abbreviated new drug applications (ANDAs) marketed by Fougera, a division of Nycomed US Inc. The products include Bacitracin; Bacitracin Zinc and Polymixin B Sulfate; Gentamicin Sulfate, Neomycin and Polymyxin B Sulfates and Bacitracin Zinc; Neomycin and Polymyxin B Sulfates and [...]

Continue reading " Fera, an Emerging Pharmaceutical Company, Acquires a Portfolio of Ophthalmic Ointments "

InSite Vision Incorporated (OTCBB:INSV) announced that Bausch & Lomb has received approval of Besivance (besifloxacin ophthalmic suspension) 0.6% for the treatment of bacterial conjunctivitis (“pink eye”) in patients one year and older from the U.S. Food and Drug Administration (FDA). Besivance is formulated with InSite Vision’s DuraSite technology, a synthetic polymer delivery vehicle that enhances [...]

Continue reading " InSite Vision Announces FDA Approval of New Ophthalmic Product Enabled by InSite’s DuraSite Technology "